Europe Intraosseous Infusion Devices Market Report

Europe Intraosseous Infusion Devices Market Size

The Europe Intraosseous Infusion Devices Market is projected to grow from USD 1.25 billion in 2025 to USD 1.33 billion in 2026 and reach USD 2.13 billion by 2034, registering a CAGR of 6.1% during the forecast period from 2026 to 2034.

The intraosseous infusion devices are medical tools designed to deliver fluids, medications, and blood products directly into the bone marrow cavity during emergency or critical care situations. These devices are primarily used when intravenous access is difficult or impossible, particularly in trauma, cardiac arrest, severe dehydration, or pediatric emergencies. Common intraosseous (IO) access points include the proximal tibia, distal femur, and humeral head, with both manual and powered insertion systems available. In Europe, the adoption of intraosseous infusion technology has been steadily increasing due to evolving emergency care protocols and growing awareness among healthcare professionals. According to the European Resuscitation Council (ERC), IO access is now recognized as a viable alternative in advanced life support scenarios, especially in pre-hospital settings where time is critical. The market is also influenced by rising ambulance call-outs across urban centers like Germany, France, and the UK, as well as an aging population prone to acute medical events.

MARKET DRIVERS

Increasing Incidence of Trauma and Cardiac Emergencies

The increasing number of trauma cases and cardiac emergencies that require quick vascular access is one of the main factors driving the growth of the Europe Intraosseous Infusion Devices Market. According to the European Society of Cardiology, over 350,000 out-of-hospital cardiac arrests occur annually across the continent and survival rates are heavily dependent on the timely administration of resuscitative drugs. In such high-pressure environments, intraosseous infusion provides a reliable and rapid alternative to traditional IV lines. For instance, according to the data from the London Ambulance Service, nearly 40% of paramedics have utilized IO devices in pre-hospital resuscitation efforts in recent years. Additionally, according to the World Health Organization's (WHO) Regional Office for Europe, over 25,000 people are killed in the region each year as a result of traffic-related injuries, many of whom need immediate fluid resuscitation. The ability of intraosseous devices to function effectively even under extreme physiological stress makes them indispensable in trauma management. This rising clinical demand continues to drive device adoption across emergency departments and ambulance services throughout Europe.

Integration of Intraosseous Access into Medical Training and Clinical Guidelines

The growing integration of intraosseous access methods into clinical guidelines and medical education is expected to boost the growth of the intraosseous infusion devices market in Europe. Over the past decade, European health authorities and professional bodies have focused on expanding the skill set of paramedics, emergency physicians, and critical care nurses to include IO access as part of standard resuscitation protocols. The European Resuscitation Council (ERC) updated its guidelines in 2021 to explicitly recommend intraosseous access as a preferred route when IV access cannot be rapidly achieved. This shift has led to widespread curriculum revisions in emergency medicine and nursing programs across countries like Germany, Sweden, and the Netherlands. Furthermore, the European Federation of Critical Care Nursing Associations (EfCCNa) has shown that hospitals and ambulance services have started to implement specific training modules for the use of IO devices.

MARKET RESTRAINTS

High Cost of Advanced Intraosseous Devices and Limited Reimbursement Policies

The high cost of advanced intraosseous devices, especially powered insertion systems, along with uneven reimbursement practices among nations, are the main factors restricting the growth of the Europe intraosseous infusion devices market. According to the European Observatory on Health Systems and Policies, disparities in healthcare funding mechanisms across EU member states result in uneven procurement capabilities. In countries like Greece and Portugal, budget constraints limit the availability of disposable IO kits and reusable insertion tools, which leads to underutilization despite clinical recommendations. Moreover, as noted by the German Institute for Medical Documentation and Information (DIMDI), several national health systems do not provide separate reimbursement codes for intraosseous procedures, which makes it financially unattractive for institutions to invest in these technologies. This lack of structured reimbursement discourages widespread adoption in public healthcare sectors where cost containment is a priority.

Risk of Complications and Lack of Long-Term Clinical Data

The inherent risks of problems,s including osteomyelitis, compartment syndrome, and extravasation, associated with intraosseous infusion devices make some doctors reluctant to use them regularly, which is another factor restraining the market growth. Although these adverse events are rare, they raise concerns about patient safety and long-term outcomes, which is limiting the broad adoption of IO access beyond acute resuscitation scenarios. According to the British Journal of Anaesthesia, there is currently little longitudinal evidence evaluating the effects of frequent or protracted IO usage on bone integrity and infection rates, even if the short-term success rates of IO access are similar to those of IV lines. The lack of knowledge hinders broader acceptance among hospital administrators and senior clinicians who prioritize evidence-based decision-making.

MARKET OPPORTUNITIES

Expansion of Pre-Hospital Emergency Care Infrastructure

Pre-hospital emergency care infrastructure in Europe is constantly growing and modernizing, which presents a significant opportunity for the intraosseous infusion devices market. Governments and healthcare organizations are increasingly investing in strengthening ambulance services, mobile intensive care units, and emergency response networks to improve patient outcomes in critical conditions. According to the European Union Agency for Fundamental Rights (FRA), emergency medical service (EMS) response times have been prioritized as a key performance indicator in healthcare quality assessments. In countries like Spain and Poland, ambulance fleet upgrades have included equipping vehicles with advanced life support equipment, such as intraosseous infusion devices. Furthermore, according to the Nordic Council of Ministers, Scandinavian countries have incorporated IO access training into paramedic curricula as part of standardized emergency treatment protocols, which guarantees widespread availability. The use of intraosseous infusion devices outside of hospitals is anticipated to increase dramatically due to an increase in ambulance calls and a greater focus on early management.

Technological Advancements in Intraosseous Device Design and Functionality

Technological innovation in intraosseous infusion devices offers a promising avenue for market growth in Europe. Manufacturers are increasingly focusing on improving device ergonomics, ease of use, and compatibility with existing emergency care workflows to enhance adoption among healthcare professionals. According to the European Association for Biomedical Research and Innovation (EABRIN), recent developments include automated insertion systems, compact handheld devices, and needle designs optimized for different anatomical sites and patient groups. These developments make IO access more attractive to a wider spectrum of doctors by reducing procedural time and minimizing complications. For example, in Switzerland, a leading medical device company introduced a next-generation IO system featuring real-time feedback sensors to confirm successful placement, which enhances user confidence and reduces errors.

MARKET CHALLENGES

Variability in Regulatory Standards Across European Countries

The difference in regulatory requirements and approval procedures across different countries in the region is a challenge for the Europe Intraosseous Infusion Devices Market. European Union allows individual member states to maintain certain nuances in medical device regulations, which creates complexities for manufacturers seeking broad market access. The time-to-market for new intraosseous infusion devices is extended in nations such as France and Italy, where local health authorities demand extra certification layers on top of the CE marking. Meanwhile, in Eastern Europe, regulatory frameworks are still evolving, which leads to uncertainties around device classification and usage protocols.

Resistance from Healthcare Professionals Due to Traditional Practice Preferences

The healthcare professionals' opposition is a major challenge for the Europe intraosseous infusion devices market. Additionally, according to a survey by the European Society of Emergency Medicine (EuSEM), over 30% of participants thought that intraosseous infusion should only be used in pediatric or mass casualty situations, which shows a limited understanding of its use. Simulation-based training nd institutional policy changes will be essential in shifting attitudes and fostering broader acceptance of intraosseous infusion as a mainstream vascular access method in European healthcare settings.

REPORT COVERAGE

SEGMENT ANALYSIS

By Product Type Insights

The EZ-IO device segment dominated the European intraosseous infusion devices market by capturing 25.4% of the market share in 2025 with its widespread adoption across emergency medical services and hospital settings due to its user-friendly design and high success rate. According to the British Journal of Anaesthesia, clinical studies have shown that EZ-IO achieves successful vascular access in over 90% of attempted cases, which is significantly higher than manual IO needles. Additionally, this device has been integrated into national emergency care protocols across Germany, the UK, and Sweden, where paramedics and critical care teams routinely use it during pre-hospital interventions. The ERC’s updated guidelines also point out that EZ-IO is a preferred option in advanced life support scenarios, which strengthens its position as the most trusted and widely used intraosseous infusion product in Europe.

The FASTx device segment is estimated to register a CAGR of 16.4% throughout the forecast period, with the increasing deployment of FASTx in pediatric emergencies and mass casualty situations where ease of use and rapid deployment are crucial. Healthcare personnel may manually insert the needle with no training because of FASTx's not having drilling or power assistance, which sets it apart from certain other IO systems. Moreover, ambulance services in Nordic countries such as Norway and Denmark have begun incorporating FASTx into standard emergency kits due to its portability and reliability in field conditions.

By Technology Insights

The battery-powered driver systems segment accounted for 45.4% of the Europe Intraosseous Infusion Devices market share in 2024. These systems offer faster and more consistent insertion compared to manual alternatives, which is particularly critical in high-stress environments such as ambulances and emergency departments. Devices like the EZ-IO and NIO utilize battery-powered drivers that allow for immediate vascular access within seconds, which reduces procedural delays and improves patient outcomes. According to the German Interdisciplinary Association for Intensive Care Medicine (DIVI), hospitals using these systems have recorded a 30% reduction in time-to-access during cardiac arrest scenarios. Furthermore, battery-powered IO devices are increasingly being adopted in mobile intensive care units across urban centers like Paris and Lyon due to their ease of integration with existing resuscitation workflows.

The manual IO needles segment is likely to grow with a CAGR of 14.7% during the forecast period, with the increased adoption in rural and resource-constrained settings where access to electricity and maintenance of powered devices may be limited. Manual IO needles, such as the Jamshidi and Dieckmann Modified Needle,e do not rely on batteries or mechanical components, which makes them highly suitable for use in remote clinics, disaster response units, and battlefield medicine. In Eastern Europe, particularly in Romania and Bulgaria, public health initiatives have promoted the use of manual IO systems in primary healthcare facilities lacking advanced infrastructure. Additionally, military and humanitarian organizations have incorporated manual IO needles into their field kits due to their durability and low cost.

By End User Insights

The hospitals segment was the largest and held 52.4% of the Europe Intraosseous Infusion Devices market share in 2025, with the integration of intraosseous access protocols into emergency departments, intensive care units, and operating theatres across major medical centers. Institutions in countries like Germany, the Netherlands, and Switzerland have standardized IO access training for emergency physicians and critical care nurses, which ensures consistent availability and utilization of these devices during acute interventions. Moreover, as per the report by the United Kingdom National Audit Project (NAP), hospitals have increasingly relied on intraosseous infusion in perioperative settings where IV access is challenging, particularly in trauma and burn patients.

The Emergency Medical Services (EMS) segment is anticipated to register a CAGR of 18.3% throughout the forecast period with the integration of IO devices into pre-hospital emergency response protocols, which enables paramedics to administer life-saving fluids and medications before reaching hospital facilities. According to the European Ambulance Network (EAN), since 2021, more than 40% of EMS services in Western Europe have outfitted their vehicles with IO kits. This is in accordance with updated European Resuscitation Council (ERC) recommendations that place a strong focus on early vascular access in situations of severe trauma and cardiac arrest. Additionally, real-time performance tracking and outcome reporting by national EMS bodies have validated the efficacy of IO use in the field, further accelerating adoption rates.

COUNTRY LEVEL ANALYSIS

Germany holds the top position in the European intraosseous infusion devices (IOID) market, accounting for approximately 28% of the regional market share in 2024, according to a report by Market Data Forecast. The country's robust healthcare infrastructure, coupled with high adoption rates of emergency care technologies, underpins its dominant market status. Germany’s advanced pre-hospital emergency response systems and widespread training programs for paramedics and first responders have significantly boosted IOID utilization. The German Red Cross and other emergency service providers have integrated IO access into standard resuscitation protocols, especially in trauma and cardiac arrest scenarios. Additionally, the presence of key manufacturers such as Becton Dickinson and Smiths Medical has further strengthened domestic supply chains. With over 75,000 annual out-of-hospital cardiac arrests the demand for rapid vascular access is growing, reinforcing the importance of IO devices. According to the European Resuscitation Council, Germany reports a 30% increase in IO device usage in ambulance settings from 2019 to 2023. Government funding for emergency medical services and continuous product innovation also supports sustained market growth.

Germany held 28.3% of the European intraosseous infusion devices (IOID) market share in 2024. Germany’s advanced pre-hospital emergency response systems and widespread training programs for paramedics and first responders have significantly boosted IOID utilization. The German Red Cross and other emergency service providers have integrated IO access into standard resuscitation protocols, especially in trauma and cardiac arrest scenarios. Additionally, the presence of key manufacturers such as Becton Dickinson and Smiths Medical has further strengthened domestic supply chains.

The United Kingdom was positioned second in Europe’s intraosseous infusion devices market by capturing 19.4% of the market share in 2024. The UK’s well-developed National Health Service (NHS), increasing emphasis on pre-hospital emergency care, and integration of IO access into national resuscitation guidelines have collectively driven market expansion. Moreover, the rising incidence of cardiovascular disease, with nearly 160,000 heart attacks occurring annually, according to the British Heart Foundation,n has increased demand for rapid fluid and drug delivery solutions. The UK also benefits from strong research activity in emergency medicine, with institutions like King’s College London conducting clinical evaluations on IO efficacy. France's intraosseous infusion devices market growth is expected to substantially grow in the coming years. France’s SAMU (Service d’Aide Médicale Urgente) plays a pivotal role in deploying IO devices in pre-hospital environments, particularly in urban centers like Paris and Marseille where emergency response times are critical. According to Santé Publique France, the nation recorded over 120,000 cardiac arrest incidents in 2023, which reinforces the need for fast-acting vascular access solutions. The French Society of Anesthesia and Intensive Care Medicine (SFAR) has actively promoted IO use in both adult and pediatric resuscitation settings.

Italy's intraosseous infusion devices market is growing steadily, with the country's aging population; more than 23% of Italians are aged 65 or older. Italy has been progressively updating its emergency medical protocols, with regions like Lombardy and Lazio leading the integration of IO devices into ambulance care. The Italian Resuscitation Council (IRC) has emphasized the importance of IO access in managing acute circulatory failure, especially in elderly patients with fragile veins. Additionally, the ongoing decentralization of healthcare management has led to varied but improving standards of emergency care across regions. Spain's intraosseous infusion devices market growth isis expectedo grow steadily in the coming years. The Spanish healthcare system has shown growing interest in IO technology within its emergency medical services (EMS). Regions such as Catalonia and Madrid have taken the lead in adopting IO devices in ambulances and critical care transport units. According to the Spanish Society of Emergency Medicine (SEMES), over 40% of pre-hospital teams in major cities now carry IO equipment as part of their standard kits. Moreover, the country recorded more than 50,000 out-of-hospital cardiac arrests in 2023, with an urgency for faster vascular access options.

KEY MARKET PLAYERS AND COMPETITIVE LANDSCAPE

Prominent Companies leading the Europe Intraosseous Infusion Devices Market Profiled in the Report are PerSys Medical, Aero Healthcare, Teleflex, Pyng Medical Corp., Biopsybell, Cook Medical Incorporated, Aero Healthcare, et,

The competition in the Europe intraosseous infusion devices market is shaped by a combination of established global players and emerging regional brands striving to capture a larger share of a growing yet highly specialized segment. Manufacturers are concentrating more on improving product usability, which includes smart technologies, and updating clinical standards in response to the growing need for quick vascular access in emergency treatment. This has led to intensified rivalry, particularly in product differentiation and post-market support services such as training and technical assistance. Companies are also expanding their reach beyond traditional hospital settings into pre-hospital emergency services, ambulance networks, and military medicine, further diversifying the competitive market. Regulatory alignment within the EU provides opportunities for streamlined market access, but varying national procurement policies and budgetary constraints continue to influence purchasing decisions across different countries.

Top Players in the Market

The Europe intraosseous infusion devices market is dominated by a few globally recognized companies that bring innovation, reliability, and clinical expertise to emergency care. Among them, Teleflex Incorporated, BD (Becton, Dickinson and Company), and Smiths Medical stand out as key players shaping the market. Teleflex Incorporated has been a pioneer in intraosseous access with its EZ-IO device, which is widely used across European hospitals and emergency services. The company’s focus on training programs, product integration into resuscitation guidelines, and continuous R&D efforts has made it a leader in the field. BD (Becton, Dickinson and Company) offers a range of medical solutions, including vascular access devices. Smith’s Medical is recognized for its comprehensive portfolio of critical care products, which includes intraosseous infusion solutions designed for both adult and pediatric applications. The company's strong distribution network and focus on clinician education have reinforced its presence in the European market.

Top Strategies Used by Key Market Participants

Leading companies in the Europe intraosseous infusion devices market are employing strategic initiatives to reinforce their competitive edge. One major approach is expanding clinical training and educational outreach, where manufacturers collaborate with healthcare institutions and emergency response agencies to promote proper device usage and build confidence among clinicians.

Another key strategy involves product innovation and technological enhancement, which focus on improving device ergonomics, ease of use, and integration with digital health platforms to enhance real-time monitoring and data collection during emergency interventions.

In order to ensure that intraosseous infusion devices are more widely available in both urban and rural healthcare settings, companies are actively participating in strategic collaborations and distribution partnerships, collaborating closely with regional distributors, governmental entities, and non-governmental organizations. These strategies collectively strengthen market position and drive adoption across diverse medical environments.

RECENT HAPPENINGS IN THE MARKET

In February 2023, Teleflex Incorporated launched an advanced version of its EZ-IO intraosseous device featuring improved insertion ergonomics and compatibility with newer emergency response protocols, which strengthened its dominance in the European market.

In September 2023, BD (Becton, Dickinson and Company) entered into a strategic distribution agreement with a leading European emergency care equipment supplier, which expands its reach of intraosseous infusion solutions across multiple countries.

In May 2024, Smiths Medical initiated a pan-European training initiative in collaboration with national emergency medicine associations with the main aim of increasing awareness and proficiency in intraosseous access techniques among paramedics and critical care staff.

In November 2024, Vyaire Medical introduced a new line of compact manual IO needles designed specifically for paediatric emergencies by targeting high-growth areas in neonatal and trauma care units across Western Europe.

In January 2025, Intercortical, a UK-based respiratory and critical care company,ny expanded its product portfolio by partnering with an Israeli medical device firm to co-develop next-generation intraosseous infusion systems integrated with digital feedback mechanisms.

MARKET SEGMENTATION

This research report on the Europe Intraosseous Infusion Devices Market has been segmented and sub-segmented into the following categories.

By Product Type

• FASTx device
• EZ-IO device

By TechnologBattery-Powered

• ed Driver
• Manual IO Needles

By End User

• Hospitals
• Emergency Medical Ambulatory Surgical Centres

By Route of Administration

• Distal Femur
• Sternum
• Distal & Proximal Tibia
• Calcaneus
• Head of Humerus

By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe